New diabetes patient survey

Diabetes charity Diabetes UK has linked up with Bristol-Myers Squibb and AstraZeneca to launch a nationwide patient survey. The aim of the study is to find out more about hypoglycaemia . Together, the pharmaceutical companies will start to market a type 2 diabetes drug called Onglyza later on this year.
The patient survey is timed to fit in with Diabetes Week next week. Chief Executive of Diabetes UK, Douglas Smallwood, reportedly commented: “Although we already know a lot about severe hypoglycaemia, little has been done to investigate mild-to-moderate episodes, which people can experience on a regular basis.”
The medical director of Astrazeneca UK, Dr. Yeoma, was meanwhile reported in the media as saying: “We hope the results of the survey will raise the understanding and awareness of mild-to-moderate hypos and lead to the improved management of type II diabetes across the UK.”